Company Overview
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
Why Investors Should Care
Net profit has compounded at 42.0% per year over the last five years.
Revenue has grown at a 58.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.25.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $276.26M (+16.5% YoY); net profit $16.52M.
- Trailing 12 Months Year-on-year growth — revenue +22.5%, earnings +59.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 58.1%, profit CAGR 42.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 58.06% |
| 1 Year: | 22.50% |
Compounded Profit Growth
| 5 Years: | 41.97% |
| 1 Year: | 59.41% |
Stock Price Performance
| 1 Year: | +6.33% |
| 6 Months: | +19.64% |
| 3 Months: | +11.10% |
| 1 Month: | -9.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)36.19 · Neutral
P/E of 84.02 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 58.1% over 5 years.
- Profit CAGR of 42.0% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 84.0.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VCEL Vericel Corporation R2KR3KPHARMA | 40.33 | 84.02 | $2.07B | 0.00% | 2.52% | 7.16% | 58.06% | 41.97% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 9.36M | 16.95M | 14.26M | - | 18.03M | 19.01M | 22.48M | 31.34M | 21.81M | 26.15M | 30.50M | 39.39M | 26.68M | 20.01M | 31.02M | - | 33.63M | 38.68M | 33.72M | 35.85M | 36.83M | 38.33M | 41.02M | 45.92M | 45.58M | 51.28M | 52.66M | 57.91M | 52.60M | 63.24M | 67.50M | 68.42M | 77.46M |
| Gross Profit | 6.69M | 4.54M | 8.19M | 7.55M | 5.52M | 4.07M | 14.96M | 2.25M | 9.28M | 7.07M | 14.96M | 10.36M | 11.28M | 14.35M | 22.71M | 13.17M | 17.13M | 21.18M | 28.80M | 16.76M | 11.35M | 22.47M | 33.65M | 22.98M | 26.91M | 22.10M | 23.45M | 22.85M | 25.23M | 26.52M | 29.94M | 30.61M | 35.35M | 36.60M | 41.65M | 36.27M | 46.61M | 49.59M | 49.27M | 56.40M |
| Operating Income | -2.27M | -4.88M | -4.96M | -1.99M | -4.98M | -6.38M | 1.19M | -9.62M | -2.52M | -4.03M | 1.19M | -4.32M | -4.25M | -1.34M | 6.00M | -3.36M | -20.20M | 3.10M | 9.21M | -5.08M | -8.36M | 3.52M | 12.29M | -3.31M | -3.73M | -4.96M | -7.27M | -9.08M | -6.79M | -8.18M | -5.96M | -5.06M | -5.46M | -6.03M | -2.46M | -12.79M | -2.03M | 3.45M | -8.06M | 434.00K |
| Net Income | -2.15M | -4.42M | -4.91M | -3.65M | -3.04M | -6.67M | 287.00K | -9.78M | -2.39M | -5.41M | 287.00K | -7.66M | -4.65M | -1.07M | 5.24M | -2.84M | -19.79M | 3.47M | 9.50M | -4.71M | -8.27M | 3.62M | 12.22M | -3.29M | -3.79M | -4.93M | -7.09M | -8.96M | -6.58M | -7.50M | -5.02M | -3.66M | -3.86M | -4.68M | -901.00K | -11.25M | -553.00K | 5.07M | -6.30M | 2.21M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | -0.21 | -0.12 | -0.02 | 0.11 | -0.07 | -0.45 | 0.07 | 0.20 | -0.10 | -0.18 | 0.08 | 0.25 | -0.07 | -0.08 | -0.11 | -0.15 | -0.19 | -0.14 | -0.16 | -0.11 | -0.08 | -0.08 | -0.10 | -0.02 | -0.23 | -0.01 | 0.10 | -0.12 | 0.04 |
| R&D Expense | 3.37M | 3.74M | - | 3.54M | 4.06M | 3.44M | - | 3.47M | 2.97M | 2.92M | - | 3.73M | 3.74M | 3.11M | - | 3.01M | 21.07M | 3.10M | - | 3.76M | 3.23M | 2.91M | - | 3.63M | 4.45M | 4.28M | 4.86M | 4.79M | 5.05M | 5.21M | 5.25M | 5.68M | 6.42M | 7.36M | 6.09M | 7.26M | 6.73M | 6.32M | 8.10M | 7.49M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 182.00K | 89.00K | 18.00K | 21.00K | 19.00K | 28.80M | 51.17M | 54.38M | 62.76M | 90.86M | 117.85M | 121.97M | 153.07M | 163.70M | 197.52M | 237.22M | 276.26M |
| Gross Profit | - | - | - | 15.00K | 15.00K | 11.50M | 24.70M | 26.08M | 33.57M | 58.70M | 80.28M | 84.23M | 106.03M | 109.79M | 135.58M | 172.11M | 205.60M |
| Operating Income | -16.17M | -17.80M | -29.04M | -33.76M | -20.96M | -23.53M | -16.67M | -19.25M | -14.98M | -3.91M | -11.25M | 2.37M | -7.85M | -17.06M | -6.46M | 4.52M | 11.04M |
| Net Income | -16.06M | -14.56M | -19.67M | -29.47M | -15.62M | -19.92M | -16.34M | -19.57M | -17.29M | -8.14M | -9.66M | 2.86M | -7.47M | -16.71M | -3.18M | 10.36M | 16.52M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.20 | -0.22 | 0.06 | -0.16 | -0.35 | -0.07 | 0.20 | 0.32 |
| R&D Expense | 11.29M | 12.66M | 21.33M | 26.02M | 15.10M | 21.26M | 18.89M | 15.29M | 12.94M | 13.60M | 30.39M | 13.02M | 16.29M | 19.94M | 21.04M | 24.80M | 27.56M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2008 | Jun 2009 | Jun 2010 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 32.83M | 7.74M | 15.18M | 9.21M | 47.58M | 34.31M | 48.60M | 54.58M | 118.69M | 153.24M | 205.61M | 243.71M | 273.00M | 353.66M | 432.72M | 487.97M |
| Total Equity | - | 16.75M | 14.78M | 2.92M | -12.97M | -32.10M | 3.89M | 35.64M | 22.13M | 24.71M | 22.54M | 102.23M | 111.09M | 134.26M | 170.46M | 192.27M | 225.95M | 291.97M | 354.64M |
| Cash & Equivalents | 16.49M | 17.00M | 14.12M | 31.25M | 5.53M | 13.64M | 8.06M | - | - | - | - | 18.29M | 26.89M | 33.62M | 68.33M | 51.07M | 69.09M | 74.52M | 100.09M |
| Long Term Debt | - | - | - | 41.00K | 40.00K | 6.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | 20.71M | 5.67M | 5.32M | 11.94M | 12.18M | 23.89M | 32.04M | 16.46M | 42.15M | 71.35M | 73.24M | 80.73M | 127.70M | 140.75M | 133.33M |
| Current Liabilities | - | - | - | 29.86M | 20.67M | 5.66M | 5.32M | 11.83M | 12.11M | 12.85M | 13.09M | 14.79M | 19.80M | 22.48M | 26.05M | 37.46M | 45.75M | 50.29M | 49.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2009 | Jun 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | -13.35M | -19.89M | -13.18M | -412.00K | -7.18M | 17.57M | 29.04M | 17.69M | 35.31M | 58.16M | 51.91M |
| Investing Cash Flow | - | - | - | - | - | - | -2.39M | -1.42M | -1.51M | -67.03M | 10.62M | -17.16M | -3.50M | -36.21M | -3.13M | -79.03M | -43.94M |
| Financing Cash Flow | - | - | - | - | - | - | -24.00K | 29.70M | 18.58M | 58.86M | 5.26M | 6.44M | 9.17M | 1.04M | 3.62M | 19.05M | 7.07M |
| Capital Expenditure | -35.00K | -120.00K | -1.03M | -273.00K | -40.00K | -829.00K | -2.43M | -1.42M | -1.51M | -2.68M | -2.62M | -2.63M | -7.92M | -7.60M | -20.01M | -63.97M | -27.16M |
| Free Cash Flow | - | - | - | - | - | - | -15.77M | -21.31M | -14.69M | -3.09M | -9.80M | 14.95M | 21.12M | 10.09M | 15.30M | -5.81M | 24.75M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2009 | Jun 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 71.4% | 78.9% | 39.9% | 48.3% | 47.9% | 53.5% | 64.6% | 68.1% | 69.1% | 69.3% | 67.1% | 68.6% | 72.6% | 74.4% |
| Operating Margin % | -8,884.1% | -20,004.5% | -161,333.3% | -160,761.9% | -110,336.8% | -81.7% | -32.6% | -35.4% | -23.9% | -4.3% | -9.5% | 1.9% | -5.1% | -10.4% | -3.3% | 1.9% | 4.0% |
| Net Margin % | -8,824.7% | -16,357.3% | -109,266.7% | -140,352.4% | -82,221.1% | -69.2% | -31.9% | -36.0% | -27.5% | -9.0% | -8.2% | 2.3% | -4.9% | -10.2% | -1.6% | 4.4% | 6.0% |
| ROE % | -95.9% | -98.5% | 151.6% | 91.8% | -401.2% | -55.9% | -73.8% | -79.2% | -76.7% | -8.0% | -8.7% | 2.1% | -4.4% | -8.7% | -1.4% | 3.5% | 4.7% |
| ROCE % | - | - | 224.6% | -354.7% | -538.4% | -65.8% | -75.1% | -53.8% | -36.1% | -3.8% | -8.4% | 1.3% | -3.6% | -7.2% | -2.1% | 1.2% | 2.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.80% | 8.09M | $331.38M |
| 2 | State Street Corporation | 6.43% | 3.29M | $134.89M |
| 3 | Congress Asset Management Co | 5.70% | 2.92M | $119.42M |
| 4 | Vanguard Capital Management LLC | 4.41% | 2.26M | $92.37M |
| 5 | Conestoga Capital Advisors, LLC | 4.07% | 2.08M | $85.33M |
| 6 | William Blair Investment Management, LLC | 3.89% | 1.99M | $81.61M |
| 7 | BNP Paribas Asset Management Holding S.A. | 3.20% | 1.64M | $67.16M |
| 8 | GW&K Investment Management, LLC | 3.03% | 1.55M | $63.49M |
| 9 | Soleus Capital Management, L.P. | 2.85% | 1.46M | $59.75M |
| 10 | Geode Capital Management, LLC | 2.62% | 1.34M | $54.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VCEL
Vericel (NASDAQ:VCEL) Stands Out on the Affordable Growth Screen - ChartMill
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPMkNTMEFubTBGNkw1el9WdzlUdFhMN2JsRVhHSjlFQVhXOWo2ekl2elFjM25scEwwRXg0Ql83VV8xeDdpSEZKODBzSU1aNmEycWFaSHpTQWx3Z1pkYTdaR05FT09jaEpEUHlFcjFweHg2OHFSTDU1V2FhZk1zeHNFUHF3NldfeDdaS2Fla3…
Liquidity Mapping Around (VCEL) Price Events - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPdnZYbUp2MFBFU0ZqaTRQRE9xS0NLWnlWZURqTWFzWUZRNXJKRzBjemRVOENiZk1rb255VVNqRnNCNmpiRDZTbmVLUmdPQzZFU1dzWGwyekVlMWNzcC0xSnR4ZGZ0cEJld0JoRURiZjFjMktXYUhfWkhLTE1mVGU2QlVlZEtsREFGdGg0MG…
Vericel Corporation (VCEL) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNYkJOb1U0LUFoc0lpVGdHdDlfWWJtSUcwb1praXpFZW0tRkFxaWl6a1FIaXJaQUwwZ3A1cXB1MVZPRl9fcE1uYm9IdkhYeEhEQW9pLWZjQUlXNG1BSm96eGcxbE1YQnpzSThEM1J5V0NUazlFcFN0aGY0Xzc1NExldnVyZWUyTnRIcWRKOH…
Vericel Authorizes $200M Buyback; Q2 Revenue Rises 22% - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQUE5JVjhabXp4QWZkbDM4bjN2UmNYQ0xaTnFvT21OOGpwNktZV2NCTzd2S2lJb3o0bDN0Tlo1V1hrLVhKYmNoUVg5eFVWVXg5cGRCMmVNckp1NjNnaWcyREs2ZTltdmlFNll1RTRjSGRTajIyQjlkRTNaMlo3RUM5Qkhmd3BmdjBlQkNJb1…
Vericel (VCEL) Stock Looks Stretched On Earnings While Its 32% Return Stays Strong - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQaTVjMVV5ZVBIaDU1V1lmekRweWZaT0h0cVNiSXI4SnJzMUdDZmFrMkJ1dmxuMlpjbEVEdzAwZDItclZCZDRLWTVqQ09MLWtBS0kyUW1ZVnVPV1FXVlBScER3YkM4YklVb0xNekdQQm5PX0RKTUd4MmdRU2swZ2NQaGJqb1RfNHB2LVNPNz…
Vericel Corp ($VCEL) CEO 2025 Pay Revealed | VCEL Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPSmxwYzZLU2hESF93eTlqd29oTTVLNU85SG9BWER1MXVnZkxzRllfSlVDTTZTRWRWOHBXY2VKSVdQLWs1ekpITTU4WmhscjV3bnN1azZ0aGUzWGRaNUNTZ2ZNSDZnRUN2dTBYelBWNC1uT1BTT1JUWnA3djd2Sk12bEtUY2NnN1Vx?oc=5"…
VCEL — Frequently Asked Questions
What is the current share price of Vericel Corporation (VCEL)?
As of 2026-09-07 16:24 PDT, Vericel Corporation (VCEL) trades at $40.33 on NasdaqGM. Its 52-week range is $29.34 to $48.31.
What is the market capitalisation of VCEL?
Vericel Corporation (VCEL) has a market capitalisation of $2.07B on NasdaqGM.
What is the P/E ratio of VCEL?
VCEL trades at a trailing price-to-earnings (P/E) ratio of 84.02. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.24.
What is the return on equity (ROE) of VCEL?
VCEL has a return on equity (ROE) of 7.16%. Its return on capital employed (ROCE) is 2.52%.
Is VCEL a good stock to buy?
This page provides a data-driven analysis of Vericel Corporation (VCEL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.